PUMA BIOTECHNOLOGY, INC. Reimbursement Revenue (Deprecated 2018-01-31)
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Reimbursement Revenue (Deprecated 2018-01-31) of $1.80 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-10.
Discontinued › Income Statement › Other Income
us-gaap:ReimbursementRevenue · last filed 2015-11-09
- PUMA BIOTECHNOLOGY, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2015-06-30 was $1.80M.
| Period end | Reimbursement Revenue (Deprecated 2018-01-31) 1 month | Reimbursement Revenue (Deprecated 2018-01-31) 3 month |
|---|---|---|
| 2015-06-30 | $1.80M 10-Q · filed 2015-11-09 | $1.80M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |